Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2 inducible kinase.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-900-4520
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees49
Next Earnings Date11/7/2019 (Estimated)
OptionableNot Optionable
Corvus Pharmaceuticals (NASDAQ:CRVS) Frequently Asked Questions
What is Corvus Pharmaceuticals' stock symbol?
Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS."
How were Corvus Pharmaceuticals' earnings last quarter?
Corvus Pharmaceuticals Inc (NASDAQ:CRVS) posted its earnings results on Thursday, August, 1st. The company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by $0.02. View Corvus Pharmaceuticals' Earnings History.
When is Corvus Pharmaceuticals' next earnings date?
What price target have analysts set for CRVS?
4 brokers have issued 12-month price objectives for Corvus Pharmaceuticals' shares. Their predictions range from $6.00 to $11.00. On average, they anticipate Corvus Pharmaceuticals' stock price to reach $8.00 in the next year. This suggests a possible upside of 145.4% from the stock's current price. View Analyst Price Targets for Corvus Pharmaceuticals.
What is the consensus analysts' recommendation for Corvus Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Corvus Pharmaceuticals.
What are Wall Street analysts saying about Corvus Pharmaceuticals stock?
Here are some recent quotes from research analysts about Corvus Pharmaceuticals stock:
- 1. Mizuho analysts commented, "We initiate coverage of CRVS at $7 PT. We like the adenosine (ADO)-A2AR pathway and believe there is promise in combination therapy. The shares have struggled due to, in our view, underwhelming ciforadenant monotherapy data but we see CPI-006 as the opportunity to reset expectations." (9/11/2019)
- 2. According to Zacks Investment Research, "Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. Corvus Pharmaceuticals, Inc. is based in Burlingame, California. " (7/15/2019)
Has Corvus Pharmaceuticals been receiving favorable news coverage?
Media coverage about CRVS stock has been trending neutral this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Corvus Pharmaceuticals earned a news sentiment score of 0.4 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Corvus Pharmaceuticals.
Are investors shorting Corvus Pharmaceuticals?
Corvus Pharmaceuticals saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 1,110,000 shares, an increase of 8.8% from the August 30th total of 1,020,000 shares. Based on an average daily volume of 145,900 shares, the days-to-cover ratio is currently 7.6 days. Currently, 5.3% of the shares of the company are sold short. View Corvus Pharmaceuticals' Current Options Chain.
Who are some of Corvus Pharmaceuticals' key competitors?
Some companies that are related to Corvus Pharmaceuticals include Merus (MRUS), Obseva (OBSV), DURECT (DRRX), XBiotech (XBIT), Kiniksa Pharmaceuticals (KNSA), Lexicon Pharmaceuticals (LXRX), ImmunoGen (IMGN), Kadmon (KDMN), AC Immune (ACIU), CytomX Therapeutics (CTMX), Neptune Wellness Solutions (NEPT), Prothena (PRTA), CymaBay Therapeutics (CBAY), MediciNova (MNOV) and OvaScience (OVAS).
What other stocks do shareholders of Corvus Pharmaceuticals own?
Who are Corvus Pharmaceuticals' key executives?
Corvus Pharmaceuticals' management team includes the folowing people:
- Dr. Richard A. Miller, Co-Founder, Pres, CEO & Chairman (Age 68)
- Mr. Leiv Lea, Chief Financial Officer (Age 65)
- Mr. Daniel W. Hunt J.D., Sr. VP & Chief Bus. Officer (Age 57)
- Dr. Joseph J. Buggy, Co-Founder & Exec. VP of Discovery Research (Age 52)
- Dr. William Benton Jones, Sr. VP of Pharmaceutical Devel. (Age 53)
When did Corvus Pharmaceuticals IPO?
(CRVS) raised $75 million in an initial public offering (IPO) on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Credit Suisse and Cowen and Company served as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.
How do I buy shares of Corvus Pharmaceuticals?
Shares of CRVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Corvus Pharmaceuticals' stock price today?
One share of CRVS stock can currently be purchased for approximately $3.26.
How big of a company is Corvus Pharmaceuticals?
What is Corvus Pharmaceuticals' official website?
How can I contact Corvus Pharmaceuticals?
Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The company can be reached via phone at 650-900-4520 or via email at [email protected]
MarketBeat Community Rating for Corvus Pharmaceuticals (NASDAQ CRVS)
| Community Ranking: | | 2.6 out of 5 ( ) |
| Outperform Votes: | | 222 (Thanks for Voting!) |
| Underperform Votes: | | 209 (Thanks for Voting!) |
| Total Votes: | | 431 |
